70 patents
Page 4 of 4
Utility
Tricyclic Compounds
30 Dec 20
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same.
Sandrine Vendeville
Filed: 26 May 20
Utility
Heterocyclic Compounds
23 Dec 20
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same.
Sandrine Vendeville, Pierre Jean-Marie Bernard Raboisson
Filed: 2 Jun 20
Utility
Modified Gapmer Oligonucleotides and Methods of Use
9 Dec 20
The disclosure includes antisense oligonucleotides, including gapmer antisense oligonucleotides, along with methods of making and use, e.g., against HBV.
Leonid Beigelman, Rajendra K. Pandey, Vivek Kumar Rajwanshi, David Bernard Smith, Jin Hong
Filed: 28 May 20
Utility
Modified Cyclic Dinucleoside Compounds As Sting Modulators
25 Nov 20
Provided herein are compounds of Formula (I), Formula (II) and/or Formula (III), or pharmaceutically acceptable salts of any of the foregoing, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same.
Leonid Beigelman, Santhosh Kumar Thatikonda, Antitsa Dimitrova Stoycheva
Filed: 5 May 20
Utility
Bicyclic and Tricyclic Compounds
18 Nov 20
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same.
Sandrine Vendeville, Pierre Jean-Marie Bernard Raboisson, Yannick Debing
Filed: 14 Apr 20
Utility
Modulators of Thr-beta and Methods of Use Thereof
11 Nov 20
Koen Vandyck, Pierre Jean-Marie Bernard RABOISSON, David McGowan, Jerome Deval
Filed: 6 May 20
Utility
Bicyclic Sulfonamides
4 Nov 20
Provided herein are compounds of Formulae (I) and (II), or pharmaceutically acceptable salts of the foregoing, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same.
Leonid Beigelman, David Bernard Smith
Filed: 11 Feb 20
Utility
Pyrrole Compounds
14 Oct 20
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same.
Sandrine Vendeville, David Bernard Smith, Leonid Beigelman, Vladimir Serebryany, Raymond F. Schinazi, Franck Amblard, Leda Bassit
Filed: 31 Mar 20
Utility
Compounds Targeting PRMT5
7 Oct 20
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same.
Koen Vandyck, Pierre Jean-Marie Bernard Raboisson, Jerome Deval, Leonid Beigelman, David McGowan, Yannick Debing
Filed: 30 Mar 20
Utility
S-antigen Transport Inhibiting Oligonucleotide Polymers and Methods
13 May 20
Various embodiments provide STOPS™ polymers that are S-antigen transport inhibiting oligonucleotide polymers, processes for making them and methods of using them to treat diseases and conditions.
Leonid Beigelman, Rajendra Pandey, Vivek Kumar Rajwanshi, David Bernard Smith, Lawrence M. Blatt, Jin Hong
Filed: 6 Nov 19